Periotherapia Co., Ltd.
About
Periotherapia Co., Ltd. is a clinical-stage biotechnology company developing innovative therapies targeting the tumor microenvironment. The company was founded based on research originating from the University of Osaka and is advancing PT0101, a humanized monoclonal antibody that selectively targets pathological periostin.
Pathological periostin is an extracellular matrix protein associated with the formation of a protective tumor microenvironment, including cancer-associated fibroblast activation, immune suppression, angiogenesis, tumor invasion, and resistance to existing cancer therapies. By neutralizing this upstream extracellular matrix driver, PT0101 is designed to remodel the tumor microenvironment and enhance the effectiveness of standard anticancer treatments.
PT0101 is currently being evaluated in a Phase 1/2a investigator-initiated clinical trial in Japan for patients with advanced solid tumors and Her2 negative metastasis/recurrent breast cancer. Periotherapia is also preparing for clinical development in North America, including combination treatment strategies with established anticancer therapies.
The company’s strategy is to establish early clinical proof of concept and biomarker-driven value internally, followed by collaboration with global pharmaceutical companies for late-stage development and commercialization. Periotherapia is seeking strategic partnerships and investment to accelerate the global development of PT0101 and deliver new treatment options for patients with serious and treatment-resistant cancers.
Areas of activity
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Additional information
企業/団体名 (日本語) / Company name in Japanese
ペリオセラピア株式会社
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術